Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance
摘要:
In our continued effort to identify selective MRP1 modulators, we have developed two novel templates, 3 and 4, through rational drug design by identifying the key pharmacophore interaction at the 7-position of the pyrrolopyrimidine template 1. Further synthesis and SAR work on these novel templates gave a number of potent MRP1 modulators with great selectivity against Pgp. Additional studies to reduce the CYP3A4 inhibition are also reported. Several compounds of these classes were subjected to in vivo xenograft studies and in vivo efficacies were demonstrated.
[EN] INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON ET LEURS PROCÉDÉS D'UTILISATION
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2018103058A1
公开(公告)日:2018-06-14
Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').
公式(I')的化合物及其使用和制备方法,以及包含公式(I')化合物的组合物。
[EN] POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] COMPOSÉS POLYCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017100662A1
公开(公告)日:2017-06-15
The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).
INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
申请人:JANSSEN PHARMACEUTICA NV
公开号:US20170283431A1
公开(公告)日:2017-10-05
The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.